Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase 4 2Phase 2/3 2Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1

Conditions

Pain 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Cancer Pain 1

Interventions

Paclitaxel 9Magnetic Resonance Spectroscopy 8Cyclophosphamide 8Cisplatin 8Carboplatin 8Granulocyte Colony-Stimulating Factor 7Etoposide 7Radiotherapy, Intensity-Modulated 6Nivolumab 6Leucovorin 6Filgrastim 6Drug Therapy 6Doxorubicin 6Radiotherapy 5Oxaliplatin 5Fluorouracil 5Docetaxel 5Bevacizumab 5pembrolizumab 4gallium 68 PSMA-11 4Taxes 4Sirolimus 4Rituximab 4Pemetrexed 4Melphalan 4Immunoglobulin G 4Gemcitabine 4Disulfides 4Dexamethasone 4Cytarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Has results × Water × Clear all
NCT01384877 2019-07-12

Subcutaneous Lidocaine For Cancer-Related Pain

British Columbia Cancer Agency

Phase 2/3 Completed
33 enrolled 16 charts

Cancer Pain, Neoplasms, Pain

NCT01379183 2016-03-21

Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility

Mayo Clinic

Phase 2/3 Completed
40 enrolled 10 charts
Endocrine

Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡